A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2013-02-17

AUTHORS

Darren R. Feldman, Lawrence H. Einhorn, David I. Quinn, Yohann Loriot, Johnathan K. Joffe, David J. Vaughn, Aude Fléchon, Julio Hajdenberg, Abdel-Baset Halim, Hamim Zahir, Robert J. Motzer

ABSTRACT

Background Tivantinib is a selective, small-molecule inhibitor of the MET receptor tyrosine kinase. Preclinical and phase 1 data suggested a possible role for MET in the pathophysiology of germ cell tumors (GCTs) and a potential clinical benefit from tivantinib in patients with these tumors. Methods Men (≥16 years) with relapsed or refractory, histologically confirmed, non-central nervous system GCTs received oral tivantinib 360 mg twice daily in 28-day cycles until progressive disease or unacceptable toxicity. The primary endpoint was objective response rate in the first 4 cycles, with study termination for <2 responses among the first 21 patients. Secondary endpoints included 12-week progression-free survival (PFS), overall survival (OS), and safety. Results Twenty-seven patients were enrolled in 9 months (median age, 32 years). Most patients had tumors with nonseminoma histology (n = 25), and primary tumor sites were testis (n = 24) and mediastinum (n = 3). Among 25 evaluable patients, no objective responses were observed; accrual was halted when the 21st patient became evaluable. Best response was stable disease (n = 5). Median PFS was 1 month, the 12-week PFS rate was 21 %, and median OS was 6 months. Grade 3 or 4 adverse events considered related to study drug included grade 3 pneumonia and grade 3 syncope (n = 1, each). Conclusions Tivantinib was well tolerated but did not demonstrate single-agent activity in patients with relapsed/refractory GCTs. Rapid accrual to this phase 2 trial was achieved in this rare patient population through multicenter collaboration. More... »

PAGES

1016-1022

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-013-9934-y

DOI

http://dx.doi.org/10.1007/s10637-013-9934-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1033162552

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23417696


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Demography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms, Germ Cell and Embryonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-met", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrrolidinones", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Memorial Sloan-Kettering Cancer Center, 1275 York Ave, 10065, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Memorial Sloan-Kettering Cancer Center, 1275 York Ave, 10065, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Feldman", 
        "givenName": "Darren R.", 
        "id": "sg:person.01275645033.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275645033.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "IU School of Medicine, Indiana University Melvin and Bren Simon Cancer Center, 535 Barnhill Drive, RT 473, 46202, Indianapolis, IN, USA", 
          "id": "http://www.grid.ac/institutes/grid.257413.6", 
          "name": [
            "IU School of Medicine, Indiana University Melvin and Bren Simon Cancer Center, 535 Barnhill Drive, RT 473, 46202, Indianapolis, IN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Einhorn", 
        "givenName": "Lawrence H.", 
        "id": "sg:person.015164347417.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015164347417.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Southern California, Norris Comprehensive Cancer Center, USC Norris Cancer Hospital, 1441 Eastlake Ave, 90033, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "University of Southern California, Norris Comprehensive Cancer Center, USC Norris Cancer Hospital, 1441 Eastlake Ave, 90033, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quinn", 
        "givenName": "David I.", 
        "id": "sg:person.01013134010.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy, University of Paris, 39 rue Camille Desmoulins, 94800, Villejuif, France", 
          "id": "http://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Institut Gustave Roussy, University of Paris, 39 rue Camille Desmoulins, 94800, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Loriot", 
        "givenName": "Yohann", 
        "id": "sg:person.0575564007.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0575564007.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "St. James University Hospital, Institute of Oncology, Beckett Street, LS9 7TF, Leeds, West Yorkshire, UK", 
          "id": "http://www.grid.ac/institutes/grid.443984.6", 
          "name": [
            "St. James University Hospital, Institute of Oncology, Beckett Street, LS9 7TF, Leeds, West Yorkshire, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Joffe", 
        "givenName": "Johnathan K.", 
        "id": "sg:person.010673061007.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010673061007.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Abramson Cancer Center, University of Pennsylvania, 16 Penn Tower, 3400 Spruce Street, 19104-4283, Philadelphia, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.412701.1", 
          "name": [
            "Abramson Cancer Center, University of Pennsylvania, 16 Penn Tower, 3400 Spruce Street, 19104-4283, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vaughn", 
        "givenName": "David J.", 
        "id": "sg:person.0756110650.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756110650.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard, 28 rue Laennec, 69008, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Centre L\u00e9on B\u00e9rard, 28 rue Laennec, 69008, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fl\u00e9chon", 
        "givenName": "Aude", 
        "id": "sg:person.0651426070.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651426070.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "M.D. Anderson Cancer Center Orlando, 1400 S. Orange Avenue, MP 700, 32806, Orlando, FL, USA", 
          "id": "http://www.grid.ac/institutes/grid.416912.9", 
          "name": [
            "M.D. Anderson Cancer Center Orlando, 1400 S. Orange Avenue, MP 700, 32806, Orlando, FL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hajdenberg", 
        "givenName": "Julio", 
        "id": "sg:person.01022066114.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022066114.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Daiichi Sankyo Pharma Development, 399 Thornall Street, 08837, Edison, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.428496.5", 
          "name": [
            "Daiichi Sankyo Pharma Development, 399 Thornall Street, 08837, Edison, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Halim", 
        "givenName": "Abdel-Baset", 
        "id": "sg:person.01134156557.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01134156557.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Daiichi Sankyo Pharma Development, 399 Thornall Street, 08837, Edison, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.428496.5", 
          "name": [
            "Daiichi Sankyo Pharma Development, 399 Thornall Street, 08837, Edison, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zahir", 
        "givenName": "Hamim", 
        "id": "sg:person.01130444357.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130444357.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Memorial Sloan-Kettering Cancer Center, 1275 York Ave, 10065, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Memorial Sloan-Kettering Cancer Center, 1275 York Ave, 10065, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Motzer", 
        "givenName": "Robert J.", 
        "id": "sg:person.01234500340.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234500340.18"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1016/s1071-5576(97)00111-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054679322", 
          "https://doi.org/10.1016/s1071-5576(97)00111-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc3205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048356671", 
          "https://doi.org/10.1038/nrc3205"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-02-17", 
    "datePublishedReg": "2013-02-17", 
    "description": "Background Tivantinib is a selective, small-molecule inhibitor of the MET receptor tyrosine kinase. Preclinical and phase 1 data suggested a possible role for MET in the pathophysiology of germ cell tumors (GCTs) and a potential clinical benefit from tivantinib in patients with these tumors. Methods Men (\u226516\u00a0years) with relapsed or refractory, histologically confirmed, non-central nervous system GCTs received oral tivantinib 360\u00a0mg twice daily in 28-day\u2009cycles until progressive disease or unacceptable toxicity. The primary endpoint was objective response rate in the first 4\u00a0cycles, with study termination for <2 responses among the first 21 patients. Secondary endpoints included 12-week progression-free survival (PFS), overall survival (OS), and safety. Results Twenty-seven patients were enrolled in 9\u00a0months (median age, 32\u00a0years). Most patients had tumors with nonseminoma histology (n\u2009=\u200925), and primary tumor sites were testis (n\u2009=\u200924) and mediastinum (n\u2009=\u20093). Among 25 evaluable patients, no objective responses were observed; accrual was halted when the 21st patient became evaluable. Best response was stable disease (n\u2009=\u20095). Median PFS was 1\u00a0month, the 12-week PFS rate was 21\u00a0%, and median OS was 6\u00a0months. Grade 3 or 4 adverse events considered related to study drug included grade 3 pneumonia and grade 3 syncope (n\u2009=\u20091, each). Conclusions Tivantinib was well tolerated but did not demonstrate single-agent activity in patients with relapsed/refractory GCTs. Rapid accrual to this phase 2 trial was achieved in this rare patient population through multicenter collaboration.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10637-013-9934-y", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2438793", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "31"
      }
    ], 
    "keywords": [
      "germ cell tumors", 
      "progression-free survival", 
      "refractory germ cell tumors", 
      "overall survival", 
      "cell tumors", 
      "median progression-free survival", 
      "phase 2 multicenter study", 
      "grade 3 pneumonia", 
      "objective response rate", 
      "median overall survival", 
      "phase 2 trial", 
      "single-agent activity", 
      "primary tumor site", 
      "rare patient population", 
      "potential clinical benefit", 
      "nonseminoma histology", 
      "evaluable patients", 
      "stable disease", 
      "PFS rates", 
      "tivantinib monotherapy", 
      "unacceptable toxicity", 
      "primary endpoint", 
      "secondary endpoints", 
      "progressive disease", 
      "most patients", 
      "objective response", 
      "adverse events", 
      "MET receptor tyrosine kinase", 
      "clinical benefit", 
      "study termination", 
      "multicenter study", 
      "patient population", 
      "Results Twenty", 
      "grade 3", 
      "phase 1 data", 
      "patients", 
      "small molecule inhibitors", 
      "Methods Men", 
      "multicenter collaboration", 
      "response rate", 
      "tumor site", 
      "tivantinib", 
      "tumors", 
      "receptor tyrosine kinases", 
      "months", 
      "good response", 
      "possible role", 
      "disease", 
      "endpoint", 
      "tyrosine kinase", 
      "survival", 
      "monotherapy", 
      "response", 
      "pneumonia", 
      "mediastinum", 
      "syncope", 
      "pathophysiology", 
      "Preclinical", 
      "histology", 
      "trials", 
      "drugs", 
      "MetS", 
      "men", 
      "inhibitors", 
      "toxicity", 
      "rate", 
      "safety", 
      "twenties", 
      "population", 
      "kinase", 
      "activity", 
      "study", 
      "role", 
      "termination", 
      "benefits", 
      "events", 
      "cycle", 
      "data", 
      "sites", 
      "accruals", 
      "collaboration"
    ], 
    "name": "A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors", 
    "pagination": "1016-1022", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1033162552"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-013-9934-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23417696"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-013-9934-y", 
      "https://app.dimensions.ai/details/publication/pub.1033162552"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:38", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_595.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10637-013-9934-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-013-9934-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-013-9934-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-013-9934-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-013-9934-y'


 

This table displays all metadata directly associated to this object as RDF triples.

310 TRIPLES      21 PREDICATES      124 URIs      114 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-013-9934-y schema:about N0dcc6abdc3de402488d56549f6a8f448
2 N2439e722269e4587a4fbce6ca590edf3
3 N628f64431d8246d7a0aa98d0be5582a4
4 N6b323f584dcf404381fcc570d072ee79
5 N71b677f9a6ec436dbeeee44d85e15bfe
6 N7f644016b0554a9cb8675a866b6ba3db
7 N8275bd1e316140c083c96fa9e27eaf23
8 N85d2ba8d6e654ad59d61196a16c74c9e
9 N880e09d1f1d946989cb0686cff59346a
10 N885cdab17f9f495eb27a9669bd75650a
11 N8d127aef32cf48f082f307018bff2b6b
12 Nae499119d27d40e583bb7b9edca054fa
13 Nca635bb6f305482a881a969339b5b158
14 Nddd241bcc2224daf9b3da007a007d8c3
15 Nf61aa872517b48e79be25ef576b12d32
16 Nfff0cfe03c8e48e798e48e1f7dda5d2d
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author N23fcbb7cc8694f45ac6cf72bf5e344cd
20 schema:citation sg:pub.10.1016/s1071-5576(97)00111-1
21 sg:pub.10.1038/nrc3205
22 schema:datePublished 2013-02-17
23 schema:datePublishedReg 2013-02-17
24 schema:description Background Tivantinib is a selective, small-molecule inhibitor of the MET receptor tyrosine kinase. Preclinical and phase 1 data suggested a possible role for MET in the pathophysiology of germ cell tumors (GCTs) and a potential clinical benefit from tivantinib in patients with these tumors. Methods Men (≥16 years) with relapsed or refractory, histologically confirmed, non-central nervous system GCTs received oral tivantinib 360 mg twice daily in 28-day cycles until progressive disease or unacceptable toxicity. The primary endpoint was objective response rate in the first 4 cycles, with study termination for <2 responses among the first 21 patients. Secondary endpoints included 12-week progression-free survival (PFS), overall survival (OS), and safety. Results Twenty-seven patients were enrolled in 9 months (median age, 32 years). Most patients had tumors with nonseminoma histology (n = 25), and primary tumor sites were testis (n = 24) and mediastinum (n = 3). Among 25 evaluable patients, no objective responses were observed; accrual was halted when the 21st patient became evaluable. Best response was stable disease (n = 5). Median PFS was 1 month, the 12-week PFS rate was 21 %, and median OS was 6 months. Grade 3 or 4 adverse events considered related to study drug included grade 3 pneumonia and grade 3 syncope (n = 1, each). Conclusions Tivantinib was well tolerated but did not demonstrate single-agent activity in patients with relapsed/refractory GCTs. Rapid accrual to this phase 2 trial was achieved in this rare patient population through multicenter collaboration.
25 schema:genre article
26 schema:isAccessibleForFree false
27 schema:isPartOf N6946fa7146cd47a2bf86bcca9acacecc
28 N769027c7b3c1409eb815d263f839adde
29 sg:journal.1094201
30 schema:keywords MET receptor tyrosine kinase
31 MetS
32 Methods Men
33 PFS rates
34 Preclinical
35 Results Twenty
36 accruals
37 activity
38 adverse events
39 benefits
40 cell tumors
41 clinical benefit
42 collaboration
43 cycle
44 data
45 disease
46 drugs
47 endpoint
48 evaluable patients
49 events
50 germ cell tumors
51 good response
52 grade 3
53 grade 3 pneumonia
54 histology
55 inhibitors
56 kinase
57 median overall survival
58 median progression-free survival
59 mediastinum
60 men
61 monotherapy
62 months
63 most patients
64 multicenter collaboration
65 multicenter study
66 nonseminoma histology
67 objective response
68 objective response rate
69 overall survival
70 pathophysiology
71 patient population
72 patients
73 phase 1 data
74 phase 2 multicenter study
75 phase 2 trial
76 pneumonia
77 population
78 possible role
79 potential clinical benefit
80 primary endpoint
81 primary tumor site
82 progression-free survival
83 progressive disease
84 rare patient population
85 rate
86 receptor tyrosine kinases
87 refractory germ cell tumors
88 response
89 response rate
90 role
91 safety
92 secondary endpoints
93 single-agent activity
94 sites
95 small molecule inhibitors
96 stable disease
97 study
98 study termination
99 survival
100 syncope
101 termination
102 tivantinib
103 tivantinib monotherapy
104 toxicity
105 trials
106 tumor site
107 tumors
108 twenties
109 tyrosine kinase
110 unacceptable toxicity
111 schema:name A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors
112 schema:pagination 1016-1022
113 schema:productId N56c0691bfe214cae95f7d3e18739824f
114 Nb535f24d3c2b48ba902fc3089d53033f
115 Ndbd59267532b432984bb485479697cde
116 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033162552
117 https://doi.org/10.1007/s10637-013-9934-y
118 schema:sdDatePublished 2022-10-01T06:38
119 schema:sdLicense https://scigraph.springernature.com/explorer/license/
120 schema:sdPublisher Ne0bd5e201bf04f01a2da6db222bfb802
121 schema:url https://doi.org/10.1007/s10637-013-9934-y
122 sgo:license sg:explorer/license/
123 sgo:sdDataset articles
124 rdf:type schema:ScholarlyArticle
125 N0724392053464e17abb35b4459c5e351 rdf:first sg:person.01234500340.18
126 rdf:rest rdf:nil
127 N0dcc6abdc3de402488d56549f6a8f448 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Neoplasms, Germ Cell and Embryonal
129 rdf:type schema:DefinedTerm
130 N1aca2e490abf4316b97d118d6f508c6c rdf:first sg:person.01130444357.38
131 rdf:rest N0724392053464e17abb35b4459c5e351
132 N23fcbb7cc8694f45ac6cf72bf5e344cd rdf:first sg:person.01275645033.21
133 rdf:rest N5b7b6873683e464c85feb4fa3b9e24cc
134 N2439e722269e4587a4fbce6ca590edf3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Adolescent
136 rdf:type schema:DefinedTerm
137 N312298bea69444a9b976f7d351d5b88b rdf:first sg:person.01022066114.86
138 rdf:rest Nc11465a5844c4f61b11a679104abfda7
139 N56c0691bfe214cae95f7d3e18739824f schema:name pubmed_id
140 schema:value 23417696
141 rdf:type schema:PropertyValue
142 N5b7b6873683e464c85feb4fa3b9e24cc rdf:first sg:person.015164347417.36
143 rdf:rest Neb0417e71a3941aa81684006f3bcfa68
144 N628f64431d8246d7a0aa98d0be5582a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Proto-Oncogene Proteins c-met
146 rdf:type schema:DefinedTerm
147 N6946fa7146cd47a2bf86bcca9acacecc schema:volumeNumber 31
148 rdf:type schema:PublicationVolume
149 N6b323f584dcf404381fcc570d072ee79 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Recurrence
151 rdf:type schema:DefinedTerm
152 N71b677f9a6ec436dbeeee44d85e15bfe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Demography
154 rdf:type schema:DefinedTerm
155 N769027c7b3c1409eb815d263f839adde schema:issueNumber 4
156 rdf:type schema:PublicationIssue
157 N7f644016b0554a9cb8675a866b6ba3db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Male
159 rdf:type schema:DefinedTerm
160 N8275bd1e316140c083c96fa9e27eaf23 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Treatment Outcome
162 rdf:type schema:DefinedTerm
163 N85d2ba8d6e654ad59d61196a16c74c9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Pyrrolidinones
165 rdf:type schema:DefinedTerm
166 N880e09d1f1d946989cb0686cff59346a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Young Adult
168 rdf:type schema:DefinedTerm
169 N885cdab17f9f495eb27a9669bd75650a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Humans
171 rdf:type schema:DefinedTerm
172 N8d127aef32cf48f082f307018bff2b6b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Adult
174 rdf:type schema:DefinedTerm
175 N98bdcf8d50854a9f96e37c7953546e05 rdf:first sg:person.0651426070.32
176 rdf:rest N312298bea69444a9b976f7d351d5b88b
177 Nae499119d27d40e583bb7b9edca054fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Disease-Free Survival
179 rdf:type schema:DefinedTerm
180 Nb535f24d3c2b48ba902fc3089d53033f schema:name doi
181 schema:value 10.1007/s10637-013-9934-y
182 rdf:type schema:PropertyValue
183 Nc11465a5844c4f61b11a679104abfda7 rdf:first sg:person.01134156557.46
184 rdf:rest N1aca2e490abf4316b97d118d6f508c6c
185 Nca635bb6f305482a881a969339b5b158 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Quinolines
187 rdf:type schema:DefinedTerm
188 Ndbd59267532b432984bb485479697cde schema:name dimensions_id
189 schema:value pub.1033162552
190 rdf:type schema:PropertyValue
191 Nddd241bcc2224daf9b3da007a007d8c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Kaplan-Meier Estimate
193 rdf:type schema:DefinedTerm
194 Ne0bd5e201bf04f01a2da6db222bfb802 schema:name Springer Nature - SN SciGraph project
195 rdf:type schema:Organization
196 Neb0417e71a3941aa81684006f3bcfa68 rdf:first sg:person.01013134010.15
197 rdf:rest Nfbc9e918b9ee48d3a364ab123a771124
198 Nec763011df9e4a6eaa1ca6b6fe2ab104 rdf:first sg:person.0756110650.00
199 rdf:rest N98bdcf8d50854a9f96e37c7953546e05
200 Nf2e804c211cb4bffaef83f9d142bdaf8 rdf:first sg:person.010673061007.33
201 rdf:rest Nec763011df9e4a6eaa1ca6b6fe2ab104
202 Nf61aa872517b48e79be25ef576b12d32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Middle Aged
204 rdf:type schema:DefinedTerm
205 Nfbc9e918b9ee48d3a364ab123a771124 rdf:first sg:person.0575564007.39
206 rdf:rest Nf2e804c211cb4bffaef83f9d142bdaf8
207 Nfff0cfe03c8e48e798e48e1f7dda5d2d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Antineoplastic Agents
209 rdf:type schema:DefinedTerm
210 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
211 schema:name Medical and Health Sciences
212 rdf:type schema:DefinedTerm
213 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
214 schema:name Clinical Sciences
215 rdf:type schema:DefinedTerm
216 sg:grant.2438793 http://pending.schema.org/fundedItem sg:pub.10.1007/s10637-013-9934-y
217 rdf:type schema:MonetaryGrant
218 sg:journal.1094201 schema:issn 0167-6997
219 1573-0646
220 schema:name Investigational New Drugs
221 schema:publisher Springer Nature
222 rdf:type schema:Periodical
223 sg:person.01013134010.15 schema:affiliation grid-institutes:grid.42505.36
224 schema:familyName Quinn
225 schema:givenName David I.
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15
227 rdf:type schema:Person
228 sg:person.01022066114.86 schema:affiliation grid-institutes:grid.416912.9
229 schema:familyName Hajdenberg
230 schema:givenName Julio
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022066114.86
232 rdf:type schema:Person
233 sg:person.010673061007.33 schema:affiliation grid-institutes:grid.443984.6
234 schema:familyName Joffe
235 schema:givenName Johnathan K.
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010673061007.33
237 rdf:type schema:Person
238 sg:person.01130444357.38 schema:affiliation grid-institutes:grid.428496.5
239 schema:familyName Zahir
240 schema:givenName Hamim
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130444357.38
242 rdf:type schema:Person
243 sg:person.01134156557.46 schema:affiliation grid-institutes:grid.428496.5
244 schema:familyName Halim
245 schema:givenName Abdel-Baset
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01134156557.46
247 rdf:type schema:Person
248 sg:person.01234500340.18 schema:affiliation grid-institutes:grid.51462.34
249 schema:familyName Motzer
250 schema:givenName Robert J.
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234500340.18
252 rdf:type schema:Person
253 sg:person.01275645033.21 schema:affiliation grid-institutes:grid.51462.34
254 schema:familyName Feldman
255 schema:givenName Darren R.
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275645033.21
257 rdf:type schema:Person
258 sg:person.015164347417.36 schema:affiliation grid-institutes:grid.257413.6
259 schema:familyName Einhorn
260 schema:givenName Lawrence H.
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015164347417.36
262 rdf:type schema:Person
263 sg:person.0575564007.39 schema:affiliation grid-institutes:grid.14925.3b
264 schema:familyName Loriot
265 schema:givenName Yohann
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0575564007.39
267 rdf:type schema:Person
268 sg:person.0651426070.32 schema:affiliation grid-institutes:grid.418116.b
269 schema:familyName Fléchon
270 schema:givenName Aude
271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651426070.32
272 rdf:type schema:Person
273 sg:person.0756110650.00 schema:affiliation grid-institutes:grid.412701.1
274 schema:familyName Vaughn
275 schema:givenName David J.
276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756110650.00
277 rdf:type schema:Person
278 sg:pub.10.1016/s1071-5576(97)00111-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054679322
279 https://doi.org/10.1016/s1071-5576(97)00111-1
280 rdf:type schema:CreativeWork
281 sg:pub.10.1038/nrc3205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048356671
282 https://doi.org/10.1038/nrc3205
283 rdf:type schema:CreativeWork
284 grid-institutes:grid.14925.3b schema:alternateName Institut Gustave Roussy, University of Paris, 39 rue Camille Desmoulins, 94800, Villejuif, France
285 schema:name Institut Gustave Roussy, University of Paris, 39 rue Camille Desmoulins, 94800, Villejuif, France
286 rdf:type schema:Organization
287 grid-institutes:grid.257413.6 schema:alternateName IU School of Medicine, Indiana University Melvin and Bren Simon Cancer Center, 535 Barnhill Drive, RT 473, 46202, Indianapolis, IN, USA
288 schema:name IU School of Medicine, Indiana University Melvin and Bren Simon Cancer Center, 535 Barnhill Drive, RT 473, 46202, Indianapolis, IN, USA
289 rdf:type schema:Organization
290 grid-institutes:grid.412701.1 schema:alternateName Abramson Cancer Center, University of Pennsylvania, 16 Penn Tower, 3400 Spruce Street, 19104-4283, Philadelphia, PA, USA
291 schema:name Abramson Cancer Center, University of Pennsylvania, 16 Penn Tower, 3400 Spruce Street, 19104-4283, Philadelphia, PA, USA
292 rdf:type schema:Organization
293 grid-institutes:grid.416912.9 schema:alternateName M.D. Anderson Cancer Center Orlando, 1400 S. Orange Avenue, MP 700, 32806, Orlando, FL, USA
294 schema:name M.D. Anderson Cancer Center Orlando, 1400 S. Orange Avenue, MP 700, 32806, Orlando, FL, USA
295 rdf:type schema:Organization
296 grid-institutes:grid.418116.b schema:alternateName Centre Léon Bérard, 28 rue Laennec, 69008, Lyon, France
297 schema:name Centre Léon Bérard, 28 rue Laennec, 69008, Lyon, France
298 rdf:type schema:Organization
299 grid-institutes:grid.42505.36 schema:alternateName University of Southern California, Norris Comprehensive Cancer Center, USC Norris Cancer Hospital, 1441 Eastlake Ave, 90033, Los Angeles, CA, USA
300 schema:name University of Southern California, Norris Comprehensive Cancer Center, USC Norris Cancer Hospital, 1441 Eastlake Ave, 90033, Los Angeles, CA, USA
301 rdf:type schema:Organization
302 grid-institutes:grid.428496.5 schema:alternateName Daiichi Sankyo Pharma Development, 399 Thornall Street, 08837, Edison, NJ, USA
303 schema:name Daiichi Sankyo Pharma Development, 399 Thornall Street, 08837, Edison, NJ, USA
304 rdf:type schema:Organization
305 grid-institutes:grid.443984.6 schema:alternateName St. James University Hospital, Institute of Oncology, Beckett Street, LS9 7TF, Leeds, West Yorkshire, UK
306 schema:name St. James University Hospital, Institute of Oncology, Beckett Street, LS9 7TF, Leeds, West Yorkshire, UK
307 rdf:type schema:Organization
308 grid-institutes:grid.51462.34 schema:alternateName Memorial Sloan-Kettering Cancer Center, 1275 York Ave, 10065, New York, NY, USA
309 schema:name Memorial Sloan-Kettering Cancer Center, 1275 York Ave, 10065, New York, NY, USA
310 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...